ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies (the "Company"), has announced that it has contracted with the clinical research organization (CRO) Averion International Corp. to conduct its planned Phase...